Skip to main content
. 2022 Oct 10;7(19):e156577. doi: 10.1172/jci.insight.156577

Figure 4. In vivo characterization of MITF-methylated melanomas.

Figure 4

(A) Photos and staining of xenograft tumors from NSG mice injected with SOX10+ (MM383) or SOX10– (IGR-39) melanoma cells. Tumors were analyzed for MITF and SOX10 protein expression using immunostaining. Arrows indicate MITF-positive melanoma cells. Original magnification, ×200. (B) Box plot showing weight differences between SOX10+ (red) and SOX10– (black) cell line–derived tumors. P value was calculated using 2-sided t test. (C) Transcriptomic analysis using the NanoString PanCancer Pathways Panel describes significant differences between SOX10+ (red) and SOX10– (black) derived xenograft tumors. (D) Box plot showing 3 selected genes (JUN, NGFR, WNT5A; FDR = 0) from the NanoString PanCancer Pathways Panel gene expression analysis. (E) Frequencies (%) of metastases detected in brain, liver, and lungs of the NSG mice injected with SOX10+ MM383 (red) and SOX10– IGR-39 (black) melanoma cells. P value was calculated using χ2 test.